Drug Development

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

AB Science's Masivet gets key FDA designation, paving the way for a new targeted cancer therapy for dogs and a major strategic win for the company.

Carterra's new 48-channel Vega platform delivers a 12-fold leap in throughput, promising to reshape primary drug screening and feed AI pharma models.

A new strategic alliance aims to bring complex peptide therapies to Europe and India, signaling a shift in global biopharma partnerships and patient access.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

South Korean biotech Galux raises a major Series B round to accelerate its AI platform, which designs novel antibody drugs from scratch with high precision.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

With five conferences in its sights, Voyager Therapeutics is making a major push to win over investors ahead of a pivotal year for its neurological pipeline.

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

With a new flexible, founder-first model, Activation Capital's Frontier BioHealth program aims to bridge the commercialization gap for life sciences startups.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

Computational chemistry firm Evogene adds world-renowned experts to guide its ChemPass AI™, aiming to accelerate drug and ag-chemical innovation.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.